Affimed to Present at the Jefferies 2019 London Healthcare Conference

Press Release - November 14, 2019

20191114_AFMD_Jefferies_final

Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 3:20 pm GMT / 10:20 am ET in London.
A live audio webcast of the presentation will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/, and will be accessible at the same link for 30 days.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat hematologic and solid tumors.

Affimed Investor and Media Contact

Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay